Between 17 and 24 million people worldwide suffer from chronic fatigue syndrome, a deeply debilitating and difficult-to-diagnose condition.
Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder | Psychedelic Invest
Vancouver, British Columbia–(Newsfile Corp. – May 30, 2024) – In a significant stride towards transforming mental health care, Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF)